REG - Victrex PLC - Q3 Interim Management Statement

VictrexAnnouncement

04/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240704:nRSD0609Va&default-theme=true

RNS Number : 0609V  Victrex PLC  04 July 2024

4 July 2024

Victrex plc - Q3 Interim Management Statement

Q3 volume & revenue growth; FY volume outlook unchanged

Victrex plc is an innovative world leader in high performance polymer
solutions, delivering sustainable products which support CO2 reduction and
enable environmental and societal benefit in multiple end-markets. Today's
Interim Management Statement for Q3 covers the period 1 April 2024 to 30 June
2024.

Performance summary: signs of top-line improvement continue into Q3

As previously communicated at interim results in May, the Group indicated it
was seeing some signs of improvement across several end-markets, primarily
within Sustainable Solutions.  Whilst sentiment across the Chemical sector
remains mixed, Victrex saw continued momentum during Q3. Group volumes showed
good progress on a year-on-year basis, up 20%. Sequentially (Q3 vs Q2), Group
volumes were flat.

Sustainable Solutions

During Q3, Value Added Resellers (VAR) saw the most improvement, compared to
the prior year, with strong volume growth, up double-digit. Aerospace,
Automotive, Electronics and Energy & Industrial delivered solid
performances compared to the prior year. Good growth in Energy volumes offset
continued softness in General Industrial, which we expect will see a slower
recovery.

 

Medical

In Medical, the impact of customer destocking continued into Q3, in line with
our guidance. We remain cautious on this business moving into our final
quarter and towards FY 2025, with no visible signs of improvement yet.
However, surgery rates continue to show good growth, which enables us to be
well positioned for when the destocking cycle ends.

 

Q3 volume & revenue:

·      Q3 Group volume up 20% to 979 tonnes (Q3 2023: 818 tonnes)

·      Q3 Group revenue up 2% at £74.0m (Q3 2023: £72.2m)

·    Q3 Average selling prices (ASP) reflected sales mix and the
continued improvement in VAR, offset by a softer Medical performance, with ASP
at £76/kg

·      Sequential volume & revenue:

o  Q3 Group volume flat compared to Q2 2024 & Q3 Group revenue down 5% vs
Q2 2024

·    Year to date Group revenue of £213.3m is 9% lower than the prior
year period (Q3 2023 YTD: £234.4m)  reflecting the softer first half year
and lower Medical revenues.

·      YTD Group volume down 2% at 2,716 tonnes (Q3 2023 YTD: 2,759
tonnes)

Robust financial position

Victrex retains a robust balance sheet, with cash generation set to improve,
driven by trading conditions, lower capital expenditure and progress on
inventory unwind. Net debt on 30 June 2024 was approximately £10m lower than
at the half year, as cash generation improved during the quarter, giving a Q3
net debt position of £39.6m (Q3 2023: £18.2m), which includes cash of
£22.7m. This was after payment of our interim dividend on 28(th) June.

 

Our guidance on full year capital expenditure and inventory is unchanged. We
anticipate capital expenditure will be lower in the second half, compared to
the first. This means full year capital expenditure will be approximately
£35m, following completion of major strategic capital investments over recent
years. Inventory is tracking to reduce in line with our guidance.

 

Outlook: FY volume guidance unchanged; H2 PBT growth requires improvement in
Medical

Jakob Sigurdsson, Chief Executive of Victrex, said: "With continued momentum
in some end markets, we remain focused on our goal of a better second half
year.  However, high inventory levels and industry destocking amongst major
medical device customers continue to be challenging for our Medical business.
At this stage, Medical performance is tracking lower than our expectations for
the second half year.

 

"On a full year basis, our volume guidance is unchanged and we continue to
expect low to mid single digit volume growth. At a profit level, destocking in
Medical and ongoing lower asset utilisation continue to be headwinds, with
currency rates starting to move adversely in the second half. Unless Medical
improves above current run-rates, the opportunity to deliver a slightly better
PBT performance in H2 2024, versus H2 2023 - in line with our previous
guidance - will be challenging. Cost discipline remains strong.

 

"The recent signs of improvement in several end-markets make growth prospects
more encouraging as we move towards FY 2025. Victrex has a diversified core
business, increasing commercialisation in our mega-programmes, well invested
assets, enhanced capability in our global team and the opportunity for
substantial cashflow improvement. Overall, we have confidence in our medium to
long-term prospects."

 

Victrex will report its FY 2024 Preliminary results on Tuesday 3(rd) December
2024.

Analyst & investor call:

A call for analysts & investors will be held today, Thursday 4(th) July,
at 08.30am UK time. To register for the call please follow this link:

Victrex Q3 Interim Management statement Registration Page!
(registrations.events) (https://registrations.events/direct/LON13497723)

 

Victrex plc:

 Andrew Hanson, Director of Investor Relations, Corporate Communications &      +44 (0) 7809 595831
 ESG
 Jakob Sigurdsson, Chief Executive                                              +44 (0) 1253 897700
 Ian Melling, Chief Financial Officer                                           +44 (0) 1253 897700

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions,
focused on the strategic markets of Automotive, Aerospace, Energy &
Industrial, Electronics and Medical. Every day, millions of people rely on
products or applications which contain our sustainable materials, from
smartphones, aeroplanes and cars to oil & gas operations and medical
devices. With over 40 years' experience, we are moving beyond the polymer into
semi-finished and finished products which shape future performance for our
customers and our markets, enable environmental and societal benefit for our
customers and drive value for our shareholders. Find out more at
www.victrexplc.com (http://www.victrexplc.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSSFWDELSEFW